A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
To determine the effect on glycemic control and lipid parameters of the 2.5 and 5 mg. doses
of BMS-298585 in drug naive subjects with Type 2 diabetes as an adjunct to diet and exercise.